North Carolina's Sprout Pharmaceuticals put together a $15 million funding round, cash the biotech will use to make another go at FDA approval for its female sexual dysfunction treatment.
Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.
Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.
Lexington, MA's Cubist Pharmaceuticals is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.
Israeli biotech NeuroDerm has secured a $16 million investment to support its work on a wearable treatment for Parkinson's disease, working through a mid-stage study on its lead candidate for the neurodegenerative ailment.
In this week's EuroBiotech Report, data on the antibiotic AstraZeneca is developing with Actavis' Forest Laboratories and some oncology compounds have burnished AstraZeneca's pipeline, a development that means the Anglo-Swedish drugmaker may now be too expensive to be attractive to Pfizer. And more.
Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal recipients of their oncology drugs.
Baxter's latest hemophilia candidate met its main goals in a late-stage study, clearing the way for an FDA application as the biopharma giant works to expand its cadre of bleeding drugs.
GlaxoSmithKline's banner respiratory division picked up another FDA approval, securing the agency's blessing for an inhaled asthma treatment as it expands its stable of drugs for airway disorders.
Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer's Enbrel in a head-to-head study. And Lilly says the results are good enough to back a regulatory filing in the first half of 2015 for its IL-17A therapy as it races to gain some new approvals following a punishing onslaught of generic competition to its top drug franchises.
With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums in Monrovia, the frenzy of attention continued to concentrate a spotlight on the sudden rush to get early-stage experimental treatments or vaccines to West Africa.
About 9 months after NovaBay Pharmaceuticals reported that its lead anti-infective therapy auriclosene had failed a Phase IIb study for impetigo, the little biotech was forced to come back and concede another setback as an opthalmic solution of the same treatment flunked a IIb for viral conjunctivitis, or pink eye, failing the primary and all secondary endpoints.
AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot at regulatory approval.
Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
Allergan, working to fend off a hostile approach from Valeant Pharmaceuticals, is reportedly taking a look at the smaller Salix Pharmaceuticals, weighing a multibillion-dollar deal that could render it unattainable--or at least drive up its asking price.
Amicus Therapeutics has come a long way in two years, shaking off a clinical misstep on the way to a second Phase III success for its rare disease treatment. Now the biotech is preparing to make its case to regulators, hoping to win approval for a new approach to Fabry disease.
Sanofi's rare ailment-focused Genzyme unit won FDA approval for a new Gaucher disease treatment, providing an oral alternative to its own trailblazing intravenous therapy.
Back in January, the prestigious Sanford-Burnham Medical Research Institute amended its ethos, promising to more closely marry its work to therapeutic development and become a partner of choice for drugmakers. Now, the 38-year-old organization has chosen the leader to get it there, convincing GlaxoSmithKline's Perry Nisen to take the reins as its new CEO.